We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
P9: Correlation between ERCC1 Expression and Response to Cisplatin in Malignant Pleural Mesothelioma.
- Authors
Mohamed Zaki, Sara Essam; Saleh, Mohamed Essam; Farrag, Amr Lotfy; El-Mahdy, Manal M.; Elhusseiny Nasr, Khaled; Kame, Tarek Hussein
- Abstract
Background: Malignant pleural mesothelioma (MPM) arises from the mesothelium lining of the pleural cavity. The disease is linked mainly to asbestos exposure. The impact of ERCC1 expression on treatment response and prognosis in MPM patients receiving Cisplatin is not yet well established Aim of the Work: To investigate the potential role of ERCC1 protein status expression as a predictive marker for efficacy of Cisplatin in MPM patients receiving treatment at Ain Shams university hospitals. Patients and Methods: Our study was carried out in Clinical Oncology Department; Ain Shams University Hospitals to investigate the potential role of ERCC1 protein status as a predictive marker for efficacy of Cisplatin-based Chemotherapy during the period from December 2015 till December 2018, with a median follow up period of 14 months. The study included 56 patients with MPM receiving Cisplatin-based chemotherapy (50 patients received Pemetrexed-Cisplatin & 6 patients received Gemzar-Cisplatin). ERCC1 was immunohistochemically detected in the paraffin blocks of all patients. CT-chest was done before starting treatment, after 3 cycles & after 6 cycles of chemotherapy then after 3 months till the end of the study. Results: We found that there was significant correlation between ERCC1 expression and objective treatment response evaluated by the modified RECIST criteria applicable to MPM where negative ERCC1 expressed patients were associated with disease stability and regression (81.1 % had SD and regression vs. 18.9 % had PD) while the highly expressed patients had disease progression (84.2 % had PD vs. 15.8 % had SD & regression) with significant P-value:<0.001.Median PFS of ERCC1 positive patients was 5 months & 12 months for ERCC1 negative patients with significant Pvalue (<0.001). Median OS was 8 months for ERCC1 positive patients & 17 months for ERCC1 negative patients also with significant P-value (<0.001). Conclusion: Our analysis indicates that positive expression of ERCC1 is associated with poor response to Cisplatin-based chemotherapy, PFS & OS
- Subjects
PLEURA cancer; CISPLATIN; MESOTHELIOMA; UNIVERSITY hospitals; PROTEIN expression; DISEASE progression
- Publication
Pan Arab Journal of Oncology, 2019, Vol 12, Issue 3, p59
- ISSN
2070-254X
- Publication type
Article